| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 17 | / | 2021 | ||||||||
| Date of issue: | 2021-05-13 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Sales revenues for April 2021 | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sofia, Bulgaria, May 13, 2021 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for April 2021 the Company recorded a decrease in sales of 22% compared to the same month of the previous year, incl. 62% increase in domestic sales and 37% decrease in export sales. In the first four months of 2021 the revenues from sales of products decrease by 29% compared to the same period of 2020, incl. 22% decrease of sales for the domestic market and 32% decrease in export sales. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Sales_Revenues_for_April_2021_espi.pdf | Sales revenues for April 2021 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2021-05-13 | Ognian Donev | Executive Director | |||
Sales_Revenues_for_April_2021_espi.pdf
